Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients
1. Univ Lille, Faculté de Médecine, CHU Lille, Laboratoire de Virologie EA3610, F-59000, Lille, France;2. CHU de Lille, Service des Maladies de l''appareil Digestif, Lille, France
Abstract:
We compared the Sanger sequencing and the commercial INNO-LiPA® HBV assay for the routine detection of precore (PC) and basal core promoter (BCP) mutations of hepatitis B virus in chronically infected patients. The overall agreement rate between assays was 94.2% and 98.8% for the detection of PC and BCP mutations, respectively.